Zileuton Production Cost Reports

The report provides a detailed analysis essential for establishing a Zileuton production plant. It encompasses all critical aspects necessary for Zileuton production, including the cost of Zileuton production, Zileuton plant cost, Zileuton production costs, and the overall Zileuton production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Zileuton production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Zileuton is an oral leukotriene synthesis inhibitor that is approved for the prophylaxis and chronic treatment of mild-to-moderate asthma. It is utilised in adults and children 12 years and older and helps to prevent symptoms like wheezing, shortness of breath, coughing, and chest tightness. It blocks leukotrienes that cause airway inflammation, swelling, and mucus buildup. It is not useful for acute asthma attacks or reversal of bronchospasm, but can be used alongside other controllers, like inhaled corticosteroids or beta-agonists. Its dosing is 600 mg immediate-release tablets four times daily or extended-release 1,200 mg twice daily after meals. It is also utilised in aspirin-exacerbated respiratory disease (AERD) and chronic urticaria because of its anti-inflammatory effects on leukotriene pathways.

The market for Zileuton is influenced by growing global asthma and COPD cases. The growing demand for leukotriene modifiers as non-steroidal long-term controllers in mild-to-moderate asthma management fuels their demand. The advancements in extended-release formulations, improving adherence, and broader healthcare access in developing markets make it a popular option. The industrial zileuton procurement is influenced by multiple API suppliers offering USDMF, CEP, and GMP-certified material, variable pricing from market dynamics and regional production. Also, regulatory filings like USDMF and JDMF for generics, and formulation preferences for tablets and extended-release driving bulk purchases further impact its sourcing strategies. The competition from dominant montelukast and zafirlukast, and the past US withdrawal of immediate-release versions, affects its market dynamics.

Raw Material for Zileuton Production

According to the Zileuton production plant project report, the key raw materials used in the production of Zileuton are N-benzyloxy-D-alanine anhydride | (2-mercaptophenyl)methyltriphenylphosphonium bromide | acetic acid 1-benzo[b]thiophen-2-yl-ethyl ester | phenyl N-hydroxycarbamate.

Production Process of Zileuton

The extensive Zileuton production cost report consists of the following major industrial production process:

1. By Coupling and Intramolecular Wittig reaction: The synthesis of Zileuton involves coupling and an intramolecular Wittig reaction. The process starts from the coupling of N-benzyloxy-D-alanine anhydride (13) and (2-mercaptophenyl)methyltriphenylphosphonium bromide to form an intermediate. This is followed by the Wittig cyclisation to construct the benzo[b]thiophene core with defined stereochemistry at the chiral centre. This is followed by deprotection and hydroxyurea formation that gives Zileuton as the final product.

Zileuton is a white, crystalline, odourless powder with a molecular formula of C11H12N2O2S and a molecular weight of 236.29 g/mol. It has a melting point of 144.2-145.2 degree Celsius with a logP value of 0.9-2.01, making it moderately lipophilic. It has a pKa value of 8.84 (strongest acidic) and a topological polar surface area of 66.6 Ų. It is practically insoluble in water and soluble in methanol, ethanol, and DMSO. It has a density of 1.401 g/cm³ and a boiling point of 449.4 degree Celsius. It shows rapid oral absorption (T_max 1.7 h), with 93% plasma protein binding.